IAVI

Pipeline

IAVI-led candidates

Our pipeline shows the progress we and our partners are making on products in development for priority infectious diseases. For information on programs where IAVI is a key partner, visit our pipeline of IAVI-supported candidates. For an explanation of development phases, visit our clinical development page.

Pipeline: IAVI-supported candidates

HIV vaccine & antibody candidates

HIV
Candidate name

eOD-GT8 60mer mRNA, coreg28v2 60mer mRNA, N332 GT5 mRNA

HIV

Partners

Gates Foundation; Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center; Duke University; Fred Hutchinson Cancer Center; Moderna; Scripps Research; Emavundleni Clinical Research Site; Desmond Tutu Health Foundation (DTHF) ; CAPRISA eThekwini; Isipingo Clinical Research Center; Setshaba Research Centre; Perinatal HIV Research Unit ; KAVI- Institute of Clinical Research; KEMRI- Wellcome Trust Research Programme

Phase 1
Clinical trial info
Candidate name

rVSVΔG-Env-HIV

HIV

Partners

Government of Japan

Pre-clinical

Emerging infectious diseases vaccine candidates

Sudan virus
Lassa virus
Marburg virus
Candidate name

rVSV∆G-SEBOV-GP

Sudan virus

Partners

Biomedical Advanced Research and Development Authority (BARDA); the World Health Organization (WHO); Uganda Virus Research Institute (UVRI); Makere Lung Institute (Uganda); Merck

Phase 1
Candidate name

rVSVΔG-LASV-GPC

Lassa virus

Partners

Batavia Biosciences; Bernhard Nocht Institute (Phase 2b); Brigham and Women’s Hospital (Phase 1); Charles River Laboratories; CliniOps; Coalition for Epidemic Preparedness; East West Medical Research Institute (Phase 1); EpiCentre; European & Developing Countries Clinical Trials Partnership; George Washington University (Phase 1); International Vaccine Institute; IQVIA; Irrua Specialist Teaching Hospital (Phase 2b); La Jolla Institute for Immunology; Kenema Government Hospital; Medical Research Council – Gambia; Merck Advisory Group; NeoGenomics Laboratories; Noguchi Memorial Institute for Medical Research, Ghana (Phase 2); Pharmalys; Phebe Hospital (Phase 2b); PREVAIL JFK Hospital Liberia (Phase 2a and 2b); PREVAIL Redemption Hospital (Phase 1); Public Health Agency of Canada; Seattle Children’s Research Institute; Tulane University; University of Liberia (Phase 2b); University of North Carolina Project Liberia (Phase 2b); University of Texas Medical Branch at Galveston; Walter Reed Program, Nigeria (Phase 2)

Phase 2
Clinical trial info
Candidate name

rVSV∆G-SUDV-GP

Sudan virus

Partners

Batavia Biosciences; Battelle; Biomedical Advanced Research and Development Authority (BARDA); BioReliance; Boston University’s National Emerging Infectious Diseases Laboratories; Charles River Laboratories; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; NeoGenomics Laboratories; Public Health Agency of Canada; Seattle Children’s Research Institute; Tulane University; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium

Phase 1
Clinical trial info
Candidate name

rVSV∆G-MARV-GP

Marburg virus

Partners

Batavia Biosciences; Battelle; Biomedical Advanced Research and Development Authority; Charles River Laboratories; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; Public Health Agency of Canada; Seattle Children’s Research Institute; Texas Biomedical Research Institute; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium

Pre-clinical

Tuberculosis (TB) vaccine candidates

Tuberculosis
Candidate name

MTBVAC

Tuberculosis

Partners

Gates Foundation; Biofabri S.L.; Open Philanthropy; Universidad de Zaragoza; the German Federal Ministry of Education and Research through the KfW Development Bank

Phase 2
Clinical trial info
Candidate name

mRNA-encoded TB antigens

Tuberculosis

Partners

Moderna; Trudeau Institute; U.S. National Institute of Allergy and Infectious Diseases; U.S. National Institutes of Health; University of Georgia

Pre-clinical